-
Pharmaceutical sector: Why India needs a regulatory pathway for biosimilar drugs
07 Mar 2024 07:53 GMT
… aid of biotechnology.
Biologicals, unlike small molecule drugs, are … biosimilar for Neupogen (India did not recognise pharmaceutical patents … doctors already have little faith in the quality of medicine … products for clinical trials and categorically allow …
-
Analyzing Amgen In Comparison To Competitors In Biotechnology Industry
25 Dec 2023 16:47 GMT
… a leader in biotechnology-based human therapeutics. Flagship drugs include red blood … and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel … 5.49
0.11%
Regeneron Pharmaceuticals Inc
24.01
3.68 … 4.64
16.08%
Biomarin Pharmaceutical Inc
123.58
3.66 …
-
Neupogen Biosimilar Nivestym Matches Efficacy for Allogeneic HSCT Donor Mobilization
05 Dec 2023 22:53 GMT
… the University of Kansas Medical Center reported new data … potential solution for managing drug shortages of biologic … dose among the 2 treatment arms. They additionally reported … Nivestym) Versus Originator Filgrastim (Neupogen) for Peripheral Blood Stem …
-
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
09 Apr 2024 13:20 GMT
… copycat of Amgen’s Neupogen became the first approved biosimilar … , the competitive prospect of drugs that mimicked pricey biologics appeared … the programs and launch with FDA approval, but I’m … in the future of prescription medicines. Payers are beginning to …
-
A three-decade monopoly: how Amgen built a patent thicket around its top-selling drug
19 Sep 2023 21:45 GMT
… to meaningful medical advances … pharmaceutical companies have a handful of these “blockbusters,” while successful biotechs … blockbuster drugs, Epogen and Neupogen, grossed … drugs like methotrexate and leflunomide, which were helpful, albeit flawed treatments …
-
FDA approves Aphexda for mobilization of stem cells before transplant in multiple myeloma
11 Sep 2023 22:06 GMT
The FDA approved motixafortide combined with filgrastim … granulocyte colony-stimulating factor filgrastim (Neupogen, Amgen).
Motixafortide blocks CXCR4 on …
-
Financial Review: TRACON Pharmaceuticals (NASDAQ:TCON) vs. Amgen (NASDAQ:AMGN)
05 Sep 2023 05:12 GMT
… ) and TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) are both medical companies … , EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen … is in Phase II clinical trial for the treatment of mesothelioma, and in …
-
Biotech firms receive $3.85 million in federal financing
10 Aug 2023 14:20 GMT
… of specialized equipment for the biotechnology sector, highlighting the teamwork … products of the following cancer treatment medicines: GCSF (Neupogen), PEG-GCSF (Neulasta), Darbepoetin … projects that boost the local pharmaceutical industry and promote the …
-
Regulatory tracker: Phathom finally nears Voquezna's commercial debut after new FDA nod
17 May 2023 16:11 GMT
… in the global FRESCO-2 trial.
Bristol Myers Squibb's Opdivo scored backing from drug reviewers at the European Medicines Agency for an approval as a presurgical neoajudvant treatment for resectable non-small cell …
-
Neutropenia Biologic Drug Treatment Global Market Report 2022: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim, Antibiotic Drugs, G-CSF, Antifungal Drugs - ResearchAndMarkets.com
17 May 2022 11:52 GMT
… in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan … Amgen's branded biologic drug, Neupogen. These less expensive alternatives increase …